RNAi news from FierceBioResearcher
NewsScreening method IDs host of HIV drug targets
A team at Harvard Medical School--led by the geneticist Dr. Stephen J. Elledge--has opened up a new slate of drug targets, identifying 273 proteins that aid HIV reproduction in cells. Because the Read more...
RNAi used as nonhormonal contraceptive
A group of researchers at Brigham and Women's Hospital in Boston are focused on developing a new, nonhormonal contraceptive that uses RNAi technology to silence the ZP3 gene, which is required to Read more...
| Press ReleasesPRESS RELEASE: Amarin Corporation to Buy Privately Held Ester Neurosciences for up to $17M Amarin Corporation to Buy Privately Held Ester Neurosciences for up to $17M LONDON, December 5 -- Amarin Corporation today announced that the Company has: - Signed an agreement to acquire Ester Read more... PRESS RELEASE: Nastech Pharmaceutical Company to Establish Subsidiary, MDRNA Nastech Pharmaceutical Company to Establish Subsidiary, MDRNA, as an Independent Company to Focus on the Development of RNA-Based Therapeutics BOTHELL, Wash., Nov. 13 -- Nastech Pharmaceutical Read more... PRESS RELEASE: Merck Licenses SNALP Technology from Protiva MERCK LICENSES SNALP TECHNOLOGY FROM PROTIVA Protiva to Receive One-Time Payment with Potential Milestone and Royalty Payments as Part of Broader Agreement VANCOUVER, BRITISH COLUMBIA--(October 16, Read more... |
Get more RNAi coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets